
bioMérieux S.A.
BMXXY
Updated: 24/09/2026, 12:26:45
bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases. Its operations span the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company provides sophisticated diagnostic platforms that analyze biological specimens to pinpoint infectious diseases, cardiovascular conditions, and various cancers. Additionally, it offers microbiological testing for quality control in manufacturing, serving the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele encompasses clinical and hospital laboratories, medical practitioners, blood banks, and industrial control facilities. Founded in 1963, the company, previously known as B-D Mérieux, maintains its headquarters in Marcy l'Etoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
No summaries found.
- Share price
- $8.97
- Market cap
- $10.58B
- Exchange
- OTC
- Currency
- USD
- CEO
- Pierre Boulud
- Employees
- 15,078
- IPO date
- 09/06/2023
- Beta
- 0.57
- Last dividend
- $0.00
- Day range
- $8.86 – $8.97
- 52-week range
- $7.12 – $14.62
- 1-day performance
- 1.36%
- 1-year performance
- 25.98%
- Current drawdown (1Y)
- -38.65%
- CIK
- N/A
- CUSIP
- 09074E101
- ISIN
- US09074E1010
- Created
- 07/12/2025, 03:03:03
- Last update
- 24/09/2026, 12:26:45
Track bioMérieux S.A. with an AI analyst
See which prediction-market events move BMXXY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.